Title:
CAR T-CELLS TARGETING BCMA AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/221873
Kind Code:
A8
Abstract:
The present application relates to the field of immunotherapy, more particularly to the field of chimeric antigen receptors (CARs). Here, CARs are proposed that are directed against B-cell Maturation Antigen (BCMA, also known as CD269). Also proposed are polynucleotides, vectors encoding the transmembrane polypeptide chains and cells expressing such CARs. These cells are particularly suitable for use in immunotherapy, and strategies to treat diseases such as cancer using these cells are also provided. The engineered immune cells, such as T-cells or natural killer (NK) cells, expressing such CARs are particularly suitable for treating lymphomas, multiple myeloma and leukemia.
Inventors:
BORNSCHEIN SIMON (BE)
BOLSÉE JENNIFER (BE)
SOTIROPOULOU PEGGY (BE)
BOLSÉE JENNIFER (BE)
SOTIROPOULOU PEGGY (BE)
Application Number:
PCT/EP2020/062064
Publication Date:
February 03, 2022
Filing Date:
April 30, 2020
Export Citation:
Assignee:
CELYAD S A (BE)
International Classes:
C07K16/28; A61K35/17; A61K39/00; A61P35/00; C07K14/705; C07K14/725; C12N15/62
Attorney, Agent or Firm:
GOODACRE, Jonathan et al. (GB)
Download PDF: